By VETTAPHARMA reporter – Derek Roche: Sun Pharmaceutical Industries reported Q4FY26 consolidated sales of Rs. 145,598 million, a 13.6% year‑on‑year (YOY) increase, and Q4 net profit of Rs. 27,140 million, up 26.2% YOY. The board took the results on record and proposed a final dividend of Rs. 5.00 per share, bringing total FY26 dividends to Rs. 16.00 per share, unchanged from FY25.
Full‑year FY26 consolidated sales reached Rs. 582,201 million, up 11.9% YOY, with EBITDA of Rs. 177,314 million (EBITDA margin 30.3%) and net profit of Rs. 114,794 million, up 5.0% YOY. R&D investment totaled Rs. 35,540 million, representing 6.1% of sales for FY26.
Segment performance highlighted continued strength in the company’s Innovative Medicines franchise. Global Innovative Medicines sales were US$ 354 million in Q4 (up 20.1%) and US$ 1,420 million for FY26 (up 16.8%), accounting for 22.2% of Q4 sales and 20.7% of full‑year sales (ex‑milestone). Sun said Innovative Medicines growth offset softness in the U.S. generics portfolio, where U.S. formulation sales were US$ 459 million in Q4, down 1.1%; U.S. sales represented ~28.8% of consolidated sales for the quarter.
Geographic and product mix: India formulations sales were Rs. 48,359 million in Q4 (up 14.8%), accounting for 33.2% of total consolidated sales. Emerging Markets formulations rose 17.4% to US$ 306 million, while Rest of World formulations increased 10% to US$ 220 million. External API sales were Rs. 6,739 million, up 26.4% in the quarter.
Management flagged pipeline and strategic milestones as growth drivers. Sun reported five novel entities in clinical development, including GL0034 (type 2 diabetes, Phase 2) and Fibromun (soft tissue sarcoma, Phase 2 completed; Phase 3 planned), and noted NidlegyTM filings and rights activity for melanoma and other indications. The company also highlighted a broad U.S. portfolio with 552 approved ANDAs and 122 ANDA filings pending, alongside 57 approved NDAs and 13 NDAs awaiting U.S. approval.
Sun reiterated its transformation strategy, citing a recent Organon acquisition expected to accelerate the company’s evolution into a global specialty player and to bolster scale in key markets. Management pointed to market‑share gains in India—market share rose from 8.1% to 8.4%—and continued product launches (11 new products in Q4; 37 in FY26) as evidence of commercial momentum.
The company will host an earnings call at 18:30 IST on May 22, 2026 to discuss results and answer investor questions. The press release did not disclose earnings per share (EPS); EPS figures will be expected in statutory filings and the investor call.
